Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study

Cihan Ay, MD, Florian Posch, MDMSc, Julia Riedl, MD, Oliver Koenigsbruegge, MD, Peter Quehenberger, MD, Christoph Zielinski, MD, Ingrid Pabinger, MD

Blood (2015) 126 (23): 653.

https://doi.org/10.1182/blood.V126.23.653.653

Published: 2015

Journal Articles

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality

Julia Riedl, Florian Posch, Eva-Maria Reitter, Ernst Eigenbauer, Christine Marosi, Ilse Schwarzinger, Christoph Zielinski, Ingrid Pabinger, Cihan Ay, MD

Blood (2014) 124 (21): 2859.

https://doi.org/10.1182/blood.V124.21.2859.2859

Published: 2014

Journal Articles

Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients – Results From the Vienna Cancer and Thrombosis Study (CATS).

Ingrid Pabinger, MD, Cihan Ay, MD, Daniela Dunkler, Johannes Thaler, Eva-Maria Reitter, Christine Marosi, Christoph Zielinski, Christine Mannhalter

Blood (2012) 120 (21): 2253.

https://doi.org/10.1182/blood.V120.21.2253.2253

Published: 2012

Journal Articles

Inhibition of NOTCH Activity by GLIOTOXIN Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells

Rainer Hubmann, Martin Hilgarth, Susanne Schnabl, Elena Ponath, Dita Demirtas, Marlies Reiter, Christoph Zielinski, Ulrich Jäger, Medhat Shehata

Blood (2011) 118 (21): 4609.

https://doi.org/10.1182/blood.V118.21.4609.4609

Published: 2011

Journal Articles

Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma and AL Amyloidosis

Wolfgang Lamm, Beatrice Schauer, Sandra Eder, Christoph Zielinski, Johannes Drach

Blood (2011) 118 (21): 5124.

https://doi.org/10.1182/blood.V118.21.5124.5124

Published: 2011

Journal Articles

Urokinase-Type Plasminogen Activator Receptor (uPAR, CD87) Regulates Integrin Redistribution in Endothelial Cells Via Interaction with Low Density Lipoprotein Receptor- (LDLR-) Like Proteins

Gerald Prager, Rene Novotny, Matthias Unseld, Marina Poettler, Waclawa Kalinowska, Johannes Breuss, Christoph Zielinski

Blood (2011) 118 (21): 5315.

https://doi.org/10.1182/blood.V118.21.5315.5315

Published: 2011

Journal Articles

Prediction of venous thromboembolism in cancer patients

Cihan Ay, Daniela Dunkler, Christine Marosi, Alexandru-Laurentiu Chiriac, Rainer Vormittag, Ralph Simanek, Peter Quehenberger, Christoph Zielinski, Ingrid Pabinger

Blood (2010) 116 (24): 5377–5382.

https://doi.org/10.1182/blood-2010-02-270116

Published: 2010

Journal Articles

Partial Characterization and In Vitro Expansion of Putative CLL Precursor/Stem Cells Which Are Dependent on Bone Marrow Microenvironment for Survival

Medhat Shehata, Rainer Hubmann, Martin Hilgarth, Susanne Schnabl, Dita Demirtas, Elina Ponath, Ekaterina Brynzak, Sabine Strommer, Volker Wachek, Alexander Hauswirth, Berthold Streubel, M.D., Katrina Vanura, Josef Schwarzmeier, Alexander Gaiger, MD, Christoph Zielinski, Peter Valent, Ulrich Jaeger

Blood (2010) 116 (21): 2433.

https://doi.org/10.1182/blood.V116.21.2433.2433

Published: 2010

Journal Articles

Urokinase Receptor (uPAR)-Dependent Integrin Redistribution Represents a Central Mechanism for Growth Factor Induced Endothelial Cell Migration

Rene Novotny, Matthias Unseld, Marina Poettler, Christoph Zielinski, Bernd Binder, Gerald Prager

Blood (2010) 116 (21): 2119.

https://doi.org/10.1182/blood.V116.21.2119.2119

Published: 2010

Journal Articles

Disturbance of B-Cell Homeostasis In Chronic Graft-Versus-Host Disease of the Lung

Zoya Kuzmina, Roman Weigl, Katharina Krenn, Ventzislav Petkov, Ulrike Koermoeczi, Arno Rottal, Christoph Zielinski, Hildegard T. Greinix, MD, Winfried Pickl

Blood (2010) 116 (21): 900.

https://doi.org/10.1182/blood.V116.21.900.900

Published: 2010

Journal Articles

Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia

Medhat Shehata, Susanne Schnabl, Dita Demirtas, Martin Hilgarth, Rainer Hubmann, Elena Ponath, Sigrun Badrnya, Claudia Lehner, Andrea Hoelbl, Markus Duechler, Alexander Gaiger, Christoph Zielinski, Josef D. Schwarzmeier, Ulrich Jaeger

Blood (2010) 116 (14): 2513–2521.

https://doi.org/10.1182/blood-2009-10-248054

Published: 2010

Includes: Supplemental data

Journal Articles

Proportions of immature CD19 + CD21 − B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease

Zoya Kuzmina, Hildegard T. Greinix, Robert Knobler, Nina Worel, Michal Kouba, Roman Weigl, Ulrike Körmöczi, Arno Rottal, David Pohlreich, Christoph Zielinski, Winfried F. Pickl

Blood (2009) 114 (3): 744–746.

https://doi.org/10.1182/blood-2009-05-221028

Published: 2009

Journal Articles

Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor

Medhat Shehata, Susanne Schnabl, Dita Demirtas, Stefanie Tauber, Martin Hilgarth, Martin Bilban, Katrina Vanura, Edit Porpaczy, Christa Fonatsch, Stephan Stilgenbauer, MD, PhD, Josef D. Schwarzmeier, Rainer Hubmann, Alexander Gaiger, Christoph Zielinski, MD, Sauveur-Michel Maira, Carlos Garcia-Echeverria, Wolfgang Hackl, Ulrich Jaeger

Blood (2008) 112 (11): 3166.

https://doi.org/10.1182/blood.V112.11.3166.3166

Published: 2008

Journal Articles

Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS)

Cihan Ay, MD, Rainer Vormittag, MD, Daniela Dunkler, PhD, Ralph Simanek, MD, Alexandru-Laurentiu Chiriac, MD, Johannes Drach, MD, Peter Quehenberger, MD, Oswald Wagner, MD, Christoph Zielinski, MD, Ingrid Pabinger, MD

Blood (2008) 112 (11): 3824.

https://doi.org/10.1182/blood.V112.11.3824.3824

Published: 2008

Journal Articles

X-Linked Inhibitor of Apoptosis Protein (XIAP) Supports Urokinase (uPA)-Induced Endothelial Cell Survival

Gerald W Prager, MD, Judit Mihaly, Patrick Brunner, MD, Christoph Zielinski, Bernd Binder, MD

Blood (2008) 112 (11): 5461.

https://doi.org/10.1182/blood.V112.11.5461.5461

Published: 2008

Journal Articles

Carcinoembryonic Antigen (CEA) Regulates Tumor-Angiogenesis in Colon Carcinomas.

Kira Braemswig, MD, Marina Poettler, BHD, Wazlawa Kalinowska, Christoph Zielinski, Gerald W Prager, MD

Blood (2008) 112 (11): 1897.

https://doi.org/10.1182/blood.V112.11.1897.1897

Published: 2008

Journal Articles

High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

Cihan Ay, Ralph Simanek, Rainer Vormittag, Daniela Dunkler, Guelay Alguel, Silvia Koder, Gabriela Kornek, Christine Marosi, Oswald Wagner, Christoph Zielinski, Ingrid Pabinger

Blood (2008) 112 (7): 2703–2708.

https://doi.org/10.1182/blood-2008-02-142422

Published: 2008

Journal Articles

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Holzer, MD, Viktoria Odelga, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2007) 110 (11): 2578.

https://doi.org/10.1182/blood.V110.11.2578.2578

Published: 2007

Journal Articles

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Viktoria Odelga, MD, Jutta Ackermann, Verena Sagaster, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2007) 110 (11): 4845.

https://doi.org/10.1182/blood.V110.11.4845.4845

Published: 2007

NARROW

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality

Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients – Results From the Vienna Cancer and Thrombosis Study (CATS).

Inhibition of NOTCH Activity by GLIOTOXIN Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells

Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma and AL Amyloidosis

Urokinase-Type Plasminogen Activator Receptor (uPAR, CD87) Regulates Integrin Redistribution in Endothelial Cells Via Interaction with Low Density Lipoprotein Receptor- (LDLR-) Like Proteins

Prediction of venous thromboembolism in cancer patients

Partial Characterization and In Vitro Expansion of Putative CLL Precursor/Stem Cells Which Are Dependent on Bone Marrow Microenvironment for Survival

Urokinase Receptor (uPAR)-Dependent Integrin Redistribution Represents a Central Mechanism for Growth Factor Induced Endothelial Cell Migration

Disturbance of B-Cell Homeostasis In Chronic Graft-Versus-Host Disease of the Lung

Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia

Proportions of immature CD19 + CD21 − B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease

Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor

Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS)

X-Linked Inhibitor of Apoptosis Protein (XIAP) Supports Urokinase (uPA)-Induced Endothelial Cell Survival

Carcinoembryonic Antigen (CEA) Regulates Tumor-Angiogenesis in Colon Carcinomas.

High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only